Tiopronin-induced membranous nephropathy: a case report

References

• Fujimoto T, Fuyuta M, Kiyofuji E, et al. Prevention by tiopronin (2-mercaptopropionyl glycine) of methylmercuric chloride-induced teratogenic and fetotoxic effects in mice. Teratology. 1979;20:297–301
   PubMedGoogle Scholar
• Fetoni AR, Quaranta N, Marchese R, et al. The protective role of tiopronin in cisplatin ototoxicity in Wistar rats. Int J Audiol. 2004;43:465–470
   PubMed Web of Science ®Google Scholar
• Chow GK, Streem SB. Medical treatment of cystinuria: Results of contemporary clinical practice. J Urol. 1996;156:1576–1578
   PubMed Web of Science ®Google Scholar
• Amor B, Mery C, de Gery A. Tiopronin (N-[2-mercaptopropionyl] glycin) in rheumatoid arthritis. Arthritis Rheum. 1982;25:698–703
   PubMed Web of Science ®Google Scholar
• Dello Strologo L, Laurenzi C, Legato A, et al. Cystinuria in children and young adults: Success of monitoring free-cystine urine levels. Pediatr Nephrol. 2007;22:1869–1873
   PubMed Web of Science ®Google Scholar
• Reveillaud RJ, Blanc G, Daudon M. Nephrotic syndrome and skin disorders appearing during alpha-mercapto-propionyl-glycine treatment of 2 cases of cystinic lithiasis. J Urol Nephrol (Paris). 1978;84:663–667
   Google Scholar
• Rizzoni G, Pavanello L, Dussini N, et al. Nephrotic syndrome during treatment with alpha-mercaptopropionylglycine. J Urol. 1979;122:381–382
   PubMed Web of Science ®Google Scholar
• Ambanelli U, Manganelli P, Ferraccioli GF. Clinical efficacy and adverse effects of tiopronin in rheumatoid arthritis. Report of a follow-up in 50 patients. Z Rheumatol. 1982;41:235–239
   Google Scholar
• Ferraccioli GF, Peri F, Nervetti A, et al. Tiopronin-nephropathy: Clinical, pathological, immunological and immunogenetic characteristics. Clin Exp Rheumatol. 1986;4:9–15
   Google Scholar
• Mordini M, Guidoni G, Maestrini M, et al. Basic treatment of rheumatoid arthritis with tiopronin. A study of 25 cases. Minerva Med. 1989;80:1019–1023
   Google Scholar
• Lindell A, Denneberg T, Enestrom S, et al. Membranous glomerulonephritis induced by 2-mercaptopropionylglycine (2-MPG). Clin Nephrol. 1990;34:108–115
   PubMed Web of Science ®Google Scholar
• Shibasaki T, Murai S, Kodama K, et al. A case of nephrotic syndrome due to alpha-mercaptopropionyl glycine in a patient with familial cystinuria. Nihon Jinzo Gakkai Shi. 1990;32:933–937
   Google Scholar
• Sany J, Combe B, Verdie-Petibon D, et al. Long-term tolerability of tiopronin (Acadione) in the treatment of rheumatoid arthritis. Apropos of 140 personal cases. Rev Rhum Mal Osteoartic. 1990;57:105–111
   Google Scholar
• Koeger AC, Palazzo E, De Person JF, et al. Subacute development of nephrotic syndrome caused by tiopronin therapy. A propos of 4 cases. Rev Rhum Ed Fr. 1993;60:78
   Google Scholar
• Asanuma H, Nakai H, Takeda M, et al. Clinical study on cystinuria in children–the stone management and the prevention of calculi recurrence. Nihon Hinyokika Gakkai Zasshi. 1998;89:758–765
   Google Scholar
• Lecoules S, Duvic C, Hérody M, et al. Tiopronin-induced nephrotic syndrome with minimal glomerular lesions. Presse Med. 1999;28:273–275
   PubMed Web of Science ®Google Scholar
• Alvarez Navascués R, Vidau Argüelles P, Rodríguez Suarez C, et al. Nephrotic syndrome and anasarca status, secondary to treatment with tiopronin in a case of cystinuria. Arch Esp Urol. 2001;54:438–440
   Google Scholar
• Tasic V, Lozanovski VJ, Ristoska-Bojkovska N, et al. Nephrotic syndrome occurring during tiopronin treatment for cystinuria. Eur J Pediatr. 2011;170:247–249
   Google Scholar
• Schwartz MM. Membranous Glomerulonephritis. Heptinstall's Pathology of the Kidney. 6th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2006:205–252
   Google Scholar
• Beck LH Jr, Salant DJ. Membranous nephropathy: Recent travels and new roads ahead. Kidney Int. 2010;77:765–770
   PubMed Web of Science ®Google Scholar
• Doi T, Mayumi M, Kanatsu K, et al. Distribution of IgG subclasses in membranous nephropathy. Clin Exp Immunol. 1984;58:57–62
   PubMed Web of Science ®Google Scholar
• Haas M. IgG subclass deposits in glomeruli of lupus and nonlupus membranous nephropathies. Am J Kidney Dis. 1994;23:358–364
   PubMed Web of Science ®Google Scholar
• Nangaku M, Couser WG. Mechanisms of immune-deposit formation and the mediation of immune renal injury. Clin Exp Nephrol. 2005;9:183–191
   PubMedGoogle Scholar
• Polanco N, Gutiérrez E, Covarsí A, et al. Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy. J Am Soc Nephrol. 2010;21:697–704
   PubMed Web of Science ®Google Scholar
• Ferraccioli GF, Nervetti A, Mercadanti M, et al. Serum IgA levels and ANA behaviour in rheumatoid patients with and without toxicity to remission-inducing drugs. Clin Exp Rheumatol. 1986;4:217–220
   Google Scholar
• Koren G. The nephrotoxic potential of drugs and chemicals. Pharmacological basis and clinical relevance. Med Toxicol Adverse Drug Exp. 1989;4:59–72
   PubMedGoogle Scholar
• Salvarani G, Macchioni P, Rossi F, et al. Nephrotic syndrome induced by tiopronin: Associated with the HLA-DR3 antigen. Arthritis Rheum. 1985;28:595–596
   Google Scholar
• Ferraccioli G, Peri F, Nervetti A, et al. Toxicity due to remission inducing drugs in rheumatoid arthritis. Assoication with HLA-B35 and Cw4 antigens. J Rheumatol. 1986;13:65–68
   Google Scholar